Novartis, the multi-national pharmaceutical company, has recently announced that the European Commission has approved Farydak (panobinostat) as a treatment for relapsed and/or refractory myeloma patients who have received at least two previous lines of treatment, including Velcade® (bortezomib) and an immunomodulatory drug. This is the first histone deacetylase (HDAC) inhibitor with epigenetic activity to be made available in the European Union, providing a new treatment option with a novel mechanism of action for patients in this setting. Based on data from the Phase III PANORAMA-1 trial, Farydak is licensed for use in combination with Velcade and dexamethasone.

Read full article